Bernstein Sees Promising Efficacy for Vertex's (VRTX) Oral RA Treatment; Shares Tick Higher
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $540.26 -2.14%
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Investors are bidding up shares of the often-momentous Vertex Pharma (Nasdaq: VRTX) Tuesday morning following some bullish comments from Bernstein's Geoffrey Page earlier. The stock last traded at $54.60, up nearly 0.9 percent on the session.
Page said efficacy for Vertex's VX 509 oral inhibitor look promising in monotherapy. The analyst believes these oral medications will eventually erode the injectables market.
Bernstein maintains an Oupterform rating and $72 price target on shares of Vertex Pharma. Page's price target implies potential upside of about 32 percent from where the stock is currently trading.
To track all the market-moving analyst action on shares of Vertex, visit our Analyst Ratings page.
Page said efficacy for Vertex's VX 509 oral inhibitor look promising in monotherapy. The analyst believes these oral medications will eventually erode the injectables market.
Bernstein maintains an Oupterform rating and $72 price target on shares of Vertex Pharma. Page's price target implies potential upside of about 32 percent from where the stock is currently trading.
To track all the market-moving analyst action on shares of Vertex, visit our Analyst Ratings page.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
- Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
